Significant Decrease in Breast Cancer Progression Achieved with Experimental Immunotherapy Combination

Significant Decrease in Breast Cancer Progression Achieved with Experimental Immunotherapy Combination
Tustin, California based biotech firm Peregrine Pharmaceuticals, Inc. has announced preclinical data that further validates the company's immune-stimulatory mechanism proprietary to its novel phosphatidylserine (PS)-targeting immuno-oncology platform. The company noted that results of new research indicate that when a PS-targeting antibody that is similar to its Bavituximab product is administered together with an anti-PD-1 antibody, statistically significant suppression of tumor growth was observed, as well as a substantial increase in the production of T-cells into the microenvironment of the tumor, in comparison to anti-PD-1 antibody treatment used alone when tested as part of an immune competent animal model for breast cancer. This new data is to be presented by Peregrine Pharmaceuticals' Vice President, Pre-Clinical Development, Jeff Hutchins, Ph.D. in a presentation entitled, "Phosphatidylserine (PS) Targeting Antibodies Enhances Activity of Immune Checkpoint Inhibitors by Repolarizing Immunosuppressive Immune Cells Populating the Tumor Microenvironment," at ImVacS, the 9th Annual Immunotherapies and Vaccine Summit hosted by Cambridge Healthtech Institute, which is set to be held from August 11-14, 2014 in Boston, Massachusetts. The company's lead product Bavituximab is also being tested in the second-line non-small cell lung cancer (NSCLC) indication in the SUNRISE pivotal Phase III clinical trial. Peregrine describes PS as "a phospholipid normally residing in the inner leaflet of the plasma membrane that becomes exposed on cells of the tumor microenvironment, promoting an immunosuppressive microenvironment (MDSCs, immature dendritic cells, M2 macrophages, anti-inflammatory cytokines). Peregrine's lead PS-targeting candidate Bavituximab in com
Subscribe or to access all post and page content.